Research
Hormonal
Tirzepatide 1-year persistence rates were 64.0% in 2023 and 64.8% in 1H 2024.
The high persistence rates for tirzepatide indicate its potential effectiveness and acceptance among patients for weight management.
StrongSupportsmedium confidence
For tirzepatide, 1-year persistence rates in 2023 and 1H 2024 (the only years the product was available) were 64.0% and 64.8%, respectively.
Why this rating
Based on the cohort study design with a large sample size.
Source
Trends in 1-year persistence and adherence among initiators of high-potency, weight loss–indicated glucagon-like peptide 1 receptor agonists
Landon Marshall et al. · Journal of Managed Care & Specialty Pharmacy · 2026
cohort · n=62650Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →